Status:
COMPLETED
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon
Lead Sponsor:
University Health Network, Toronto
Conditions:
Diabetes
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
Insulin resistant states are characterized by hepatic lipoprotein (VLDL) particle overproduction. Numerous hormonal and nutritional factors are known to influence hepatic lipoprotein particle producti...
Detailed Description
Potential role of glucagon in intestinal and hepatic lipoprotein production. Although glucagon, the main hormone that opposes insulin action, is known to exert profound effects on carbohydrate (stimul...
Eligibility Criteria
Inclusion
- Men and women, aged 18 to 40 years
- Body mass index 20 kg/m2 to 25 kg/m2
- Hemoglobin above 130g/L.
- Normal glucose tolerance in response to a 75g, 2-hr OGTT
Exclusion
- Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.
- Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \> 100 or systolic \> 180) or proliferative retinopathy
- Fasting blood glucose \> 6.0 mmol/l or known diabetes.
- Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.
- Any laboratory values: AST \> 2x ULN; ALT \> 2x ULN TSH \> 6 mU/l
- Current addiction to alcohol or substances of abuse as determined by the investigator.
- Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
- Taking any prescription or non-prescription medications at the time of the study
- Having donated blood three months prior to and three months post study procedures
- A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01155206
Start Date
June 1 2009
End Date
January 1 2010
Last Update
December 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4